EP1117833A1 - Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux - Google Patents

Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux

Info

Publication number
EP1117833A1
EP1117833A1 EP99950047A EP99950047A EP1117833A1 EP 1117833 A1 EP1117833 A1 EP 1117833A1 EP 99950047 A EP99950047 A EP 99950047A EP 99950047 A EP99950047 A EP 99950047A EP 1117833 A1 EP1117833 A1 EP 1117833A1
Authority
EP
European Patent Office
Prior art keywords
levels
cancer
patient
cells
tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99950047A
Other languages
German (de)
English (en)
Other versions
EP1117833A4 (fr
Inventor
Roberto A. Macina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1117833A1 publication Critical patent/EP1117833A1/fr
Publication of EP1117833A4 publication Critical patent/EP1117833A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging prognosticating, imaging and treating cancers, particularly gastrointestinal cancers including cancer of the stomach, small intestine and colon.
  • BACKGROUND OF THE INVENTION Cancer of the colon is the second most frequently diagnosed malignancy in the United States, as well as the second most common cause of cancer death.
  • Colon cancer is a highly treatable and often curable disease when localized to the bowel.
  • Surgery is the primary treatment and results in cure in approximately 50% of patients.
  • recurrence and metastases following surgery is a major problem and often is the ultimate cause of death.
  • cancer of the colon Due to its proximity, cancer of the colon often metastasizes to the small intestine.
  • the prognosis of the cancer spreading to the small intestine is related to the degree of penetration of the tumor through the bowel wall and the presence or absence of nodal involvement. These two characteristics form the basis for all staging systems developed for colon cancer.
  • Various characteristics also assist in prognosticating colon cancer and its spread to the small intestines. For example, bowel obstruction and bowel perforation are indicators of poor prognosis. Elevated pretreatment serum levels of carcinoembryonic antigen (CEA) and of carbohydrate antigen 19-9 (CA 19-9) also have a negative prognostic significance.
  • age greater than 70 years at presentation is not a contraindication to standard therapies; acceptable morbidity and mortality, as well as long-term survival, are achieved in this patient population.
  • Cancer cells can also originate in the small intestine. However, this is a much rarer type of cancer. Symptoms of cancer of the small intestine typically include pain or cramps in the middle of the abdomen, weight loss without dieting, a lump in the abdomen or blood in the stool .
  • Cancer of the stomach also referred to as gastric cancer, also frequently metastasizes to the small intestine due to its proximity. This cancer is often difficult to diagnose in early stages and can be in the stomach for a long time, growing to a large size before symptoms arise.
  • an individual may experience indigestion and stomach discomfort, a bloated feeling after eating, mild nausea, loss of appetite or heartburn.
  • Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating cancer of the colon, small intestine or stomach are of critical importance to the outcome of the patient. Patients diagnosed with early stage cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized cancers. New diagnostic methods which are more sensitive and specific for detecting early cancer of the stomach, small intestine and colon are clearly needed.
  • gastrointestinal cancers are closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a cancer marker which is more sensitive and specific in detecting recurrence of these types of cancer .
  • Another important step in managing gastrointestinal cancers is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy.
  • pathological staging of cancer is preferable over clinical staging because the former gives a more accurate prognosis.
  • clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of gastrointestinal cancers would be improved by identifying new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion.
  • CSG1-13 Thirteen colon specific genes and naturally occurring variants thereof, referred to as CSG1-13, are disclosed in U.S. Patent 5,733,748 and WO 96/39541 for use as diagnostic markers in colon cancer. Some of these genes and polypeptides encoded thereby are also taught to be useful in determining if the colon cancer has metastasized.
  • This gene and the polypeptide encoded thereby are similar in sequence to the cancer specific gene referred to herein as CC2. It has now been found that CC2 is a useful diagnostic and metastatic marker not only for colon cancer but also for cancer of the stomach and small intestine.
  • methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating gastrointestinal cancers including cancer of the stomach, small intestine and colon via the cancer specific gene referred to herein as CC2.
  • CC2 refers, among other things, to native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:l.
  • the amino acid sequence of a polypeptide encoded by SEQ ID NO:l is depicted herein as SEQ ID NO:2.
  • SEQ ID NO:2 means the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO : 1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:l.
  • a method of diagnosing metastatic cancer m a patient having a gastrointestinal cancer which is not known to have metastasized by identifying a human patient suspected of having a gastrointestinal cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing the CC2 levels m such cells, tissues, or bodily fluid with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase m CC2 levels in the patient versus the normal human control is associated with a gastrointestinal cancer which has metastasized.
  • Also provided by the invention is a method of staging a gastrointestinal cancer m a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing CC2 levels in such cells, tissues, or bodily fluid with levels of CC2 m preferably the same cells, tissues, or bodily fluid tyoe of a normal human control sample, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is associated with a cancer which is regressing or m remission.
  • the method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2 ; comparing the CC2 levels m such cells, tissue, or bodily fluid with levels of CC2 m preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a cancer which has metastasized.
  • a method of monitoring the change in stage of a gastrointestinal cancer in a human having such cancer by looking at levels of CC2 in a human having such cancer comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing the CC2 levels in such cells, tissue, or bodily fluid with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is associated with a cancer which is regressing or in remission.
  • antibodies targeted against CC2 or fragments of such antibodies which can be used to detect or image localization of CC2 in a patient for the purpose of detecting or diagnosing a disease or condition.
  • Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques .
  • the term "antibody”, as used herein and throughout the instant specification is also meant to include aptamers and single- stranded oligonucleotides such as those derived from an in vi tro evolution protocol referred to as SELEX and well known to those skilled in the art.
  • Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals.
  • antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of CC2.
  • the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodru .
  • the present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers by comparing levels of CC2 with those of CC2 in a normal human control.
  • levels of CC2 as used herein means levels of the native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:l.
  • the amino acid sequence of a polypeptide encoded by SEQ ID NO:l is depicted herein as SEQ ID NO:2.
  • levels of CC2 means levels of the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:l or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:l. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels.
  • a diagnostic assay in accordance with the invention for diagnosing overexpression of CC2 protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, and in particular gastrointestinal cancers.
  • gastrointestinal cancers it is meant to include stomach cancer, cancer of the small intestine, and colon cancer.
  • All the methods of the present invention may optionally include measuring levels of other cancer markers as well as CC2.
  • Other cancer markers, in addition to CC2, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.
  • Diagnostic Assays The present invention provides methods for diagnosing the presence of a gastrointestinal cancer by analyzing for changes in levels of CC2 in cells, tissues or bodily fluids compared with levels of CC2 in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein a change in levels of CC2 in the patient versus the normal human control is associated with the presence of a gastrointestinal cancer.
  • a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CC2, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.
  • the cancer marker such as CC2
  • the present invention also provides a method of diagnosing the onset of metastatic gastrointestinal cancers in a patient having a gastrointestinal cancer which has not yet metastasized.
  • a human cancer patient suspected of having a gastrointestinal cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.
  • determining the presence of CC2 levels in cells, tissues or bodily fluid is particularly useful for discriminating between gastrointestinal cancers which have not metastasized and gastrointestinal cancers which have metastasized.
  • Existing techniques have difficulty discriminating between gastrointestinal cancers which have metastasized and gastrointestinal cancers which have not metastasized. However, proper treatment selection is often dependent upon such knowledge.
  • the cancer marker level measured in cells, tissues or bodily fluid of a human patient is CC2.
  • the measured CC2 level in the human patient is compared with levels of CC2 in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CC2 in serum, this level is preferably compared with the level of CC2 in serum of a normal human control .
  • An increase in the CC2 in the patient versus the normal human control is associated with a gastrointestinal cancer which has metastasized.
  • a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CC2, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal patient.
  • Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably also include samples from a human patient that is determined by reliable methods to have a gastrointestinal cancer which has not metastasized.
  • the invention also provides a method of staging gastrointestinal cancers in a human patient.
  • the method comprises identifying a human patient having such cancer and analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2.
  • CC2 levels m such cells, tissues or bodily fluid are then compared with levels of CC2 m preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase m CC2 levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is associated with a cancer which is regressing or m remission .
  • a method of monitoring gastrointestinal cancers in a human having such cancer for the onset of metastasis comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2; comparing the CC2 levels m such cells, tissues or bodily fluid with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase m CC2 levels m the human patient versus the normal human control is associated with a cancer which has metastasized.
  • a method of monitoring the change in stage of gastrointestinal cancers in a human having such cancer is identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2; comparing the CC2 levels m such cells, tissues or bodily fluid with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control, where
  • the method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2; and comparing the CC2 levels in such cells, tissues or bodily fluid with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CC2 levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CC2 is associated with a cancer which is regressing in stage or in remission .
  • Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis.
  • Assay Techniques Assay techniques that can be used to determine levels of gene expression (including protein levels), such as CC2 of the present invention, in a sample derived from a patient are well known to those of skill in the art.
  • Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, in si tu hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling.
  • RT-PCR reverse transcriptase PCR
  • immunohistochemistry assays in si tu hybridization assays
  • competitive-binding assays Western Blot analyses
  • ELISA assays and proteomic approaches two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling.
  • ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.
  • An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CC2 , preferably a monoclonal antibody.
  • a reporter antibody generally is prepared which binds specifically to CC2.
  • the reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.
  • a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.
  • antibody specific to CC2 is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin.
  • the sample to be analyzed is incubated m the dish, during which time CC2 binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CC2 and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CC2. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CC2 antibodies, produces a colored reaction product. The amount of color developed m a given time period is proportional to the amount of CC2 protein present in the sample.
  • Quantitative results typically are obtained by reference to a standard curve.
  • a competition assay can also be employed wherein antibodies specific to CC2 are attached to a solid support and labeled CC2 and a sample derived from the host are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of CC2 in the sample.
  • Nucleic acid methods can also be used to detect CC2 mRNA as a marker for gastrointestinal cancers.
  • Polymerase chain reaction (PCR) and other nucleic acid methods such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA) , can be used to detect malignant cells for diagnosis and monitoring of various malignancies.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • NASABA nucleic acid sequence based amplification
  • RT- PCR reverse-transcriptase PCR
  • RT- PCR is a powerful technique which can be used to detect the presence of a specific mRNA population m a complex mixture of thousands of other mRNA species.
  • RT-PCR an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.
  • cDNA complementary DNA
  • RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.
  • Hybridization to clones or oligonucleotides arrayed on a solid support can be used to detect both the expression of and quantitate the level of expression of a gene.
  • a cDNA encoding the CC2 gene is fixed to a substrate .
  • the substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic.
  • At least a portion of the DNA encoding the CC2 gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.
  • Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by m vi tro transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.
  • 2D electrophoresis is a technique well known to those m the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample .
  • Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof.
  • Blood can include whole blood, plasma, serum or any derivative of blood.
  • Antibodies which specifically bind to CC2 can also be used in vivo in patients suspected of suffering from gastrointestinal cancers including stomach cancer, cancer of the small intestine, and colon cancer. Specifically, antibodies which specifically bind a CC2 can be injected into a patient suspected of having a gastrointestinal cancer for diagnostic and/or therapeutic purposes.
  • the preparation and use of antibodies for in vivo diagnosis is well known in the art.
  • antibody-chelators labeled with Indium-Ill have been described for use in the radioimmunoscintographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al . Nucl . Med. Biol. 1990 17:247-254).
  • these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al . J. Clin. One. 1991 9:631-640) .
  • Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342).
  • Antibodies directed against CC2 can be used in a similar manner.
  • Labeled antibodies which specifically bind CC2 can be injected into patients suspected of having a gastrointestinal cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used.
  • radioactive labels such as Indium-Ill, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT) .
  • Positron emitting labels such as Fluorine-19 can be used in positron emission tomography.
  • Paramagnetic ions such as Gadliniu (III) or Manganese (II) can be used in magnetic resonance imaging (MRI) . Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.
  • an antibody which specifically binds CC2 can also have a therapeutic benefit.
  • the antibody may exert its therapeutic effect alone.
  • the antibody may be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect.
  • Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648.
  • Yttrium- 90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680) .
  • Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CC2.
  • Antibodies which can be used in these in vivo methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques .
  • Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.
  • Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase.
  • the method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5 ' reporter dye and a downstream 3 ' quencher dye.
  • Taqman internal fluorescent oligonucleotide probe
  • the 5'- 3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System ( PE Applied Biosystems, Foster City, CA, USA) .
  • Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency.
  • Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous control.
  • GPDH glyceraldehyde-3-phosphate dehydrogenase
  • rRNA 18S ribosomal RNA
  • Table 1 The absolute numbers depicted in Table 1 are relative levels of expression of CC2 in 12 normal different tissues. All the values are compared to normal kidney (calibrator) . These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals. Table 1 Relative Levels of CC2 Expression in Pooled Samples
  • Table 1 The relative levels of expression in Table 1 show that the higher level of expression of CC2 mRNA is in tissues from the gastrointestinal tract, small intestine (2539) , stomach (2062), and colon (536), with a lower level of expression in prostate (332), and testis (112). These results establish that CC2 mRNA expression is highly specific for gastrointestinal tissues including not only the colon but also the small intestine and stomach.
  • the absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They should not be compared to the absolute numbers originated from RNA obtained from tissue samples of single individuals depicted in Table 2.
  • Table 2 The absolute numbers depicted in Table 2 are relative levels of expression of CC2 in 78 pairs of matching samples. All the values are compared to normal kidney (calibrator) . A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Table 2: Relative Levels of CC2 Expression in Pooled Samples
  • Table 2 shows overexpression of CC2 in 15 primary stomach cancer tissues compared with their respective normal adjacent (stomach samples #3, 4, 5, 6, 7, 8, 9, 11, 13, 14, 15, 16, 17, 19, and 20) . There is overexpression in the cancer tissues for 75% of the stomach matching samples tested (total of 20 stomach matching samples) .
  • CC2 is also differentially expressed in the two tested matching samples for cancer of the small intestine.
  • Sample #1 shows upregulation for the mRNA of CC2 in cancer
  • sample #2 shows lower expression in cancer
  • CC2 is differentially expressed in twenty-three matching samples for colon cancer.
  • Samples #1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 13, 16, 17, 19, 20, 21 and 22 show upregulation for the mRNA of CC2 in cancer
  • samples #9, 12, 14, 15, 18, and 23 show lower expression in the cancer sample when compared to the normal adjacent tissue.
  • CC2 tissue specificity for gastrointestinal tissues, plus the mRNA differential expression in several of the primary stomach, small intestine, and colon matching samples tested indicate CC2 to be a diagnostic marker for gastrointestinal cancers including not only colon cancer, but also stomach cancer and cancer of the small intestine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un nouveau procédé pour détecter, diagnostiquer, surveiller, établir la stadification, faire des prévisions, obtenir des images et procéder à un traitement en rapport avec des cancers gastro-intestinaux, y compris ceux de l'intestin grêle, du côlon et de l'estomac.
EP99950047A 1998-10-02 1999-09-30 Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux Withdrawn EP1117833A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10287998P 1998-10-02 1998-10-02
US102879P 1998-10-02
PCT/US1999/022725 WO2000020640A1 (fr) 1998-10-02 1999-09-30 Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux

Publications (2)

Publication Number Publication Date
EP1117833A1 true EP1117833A1 (fr) 2001-07-25
EP1117833A4 EP1117833A4 (fr) 2002-08-14

Family

ID=22292156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99950047A Withdrawn EP1117833A4 (fr) 1998-10-02 1999-09-30 Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux

Country Status (4)

Country Link
EP (1) EP1117833A4 (fr)
JP (1) JP2002526760A (fr)
CA (1) CA2345000A1 (fr)
WO (1) WO2000020640A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962779B1 (en) 1998-10-02 2005-11-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
ES2548381T3 (es) 2000-03-27 2015-10-16 Thomas Jefferson University Composiciones para el tratamiento e imágenes de células de cáncer estomacales y de esófago
WO2002000939A2 (fr) * 2000-06-28 2002-01-03 Diadexus, Inc. Procede de diagnostic, de surveillance, de determination du stade, d'imagerie et de traitement du cancer du colon
AU784548B2 (en) 2001-03-16 2006-04-27 Ortho-Clinical Diagnostics, Inc. Reg-like protein
WO2005021709A2 (fr) * 2003-05-29 2005-03-10 Diadexus, Inc. Compositions d'anticorps anti-cln101 et procedes d'utilisation de ces compositions, seules ou combinees a un antigene prostatique specifique et a d'autres marqueurs du cancer
US20060134653A1 (en) * 2004-07-28 2006-06-22 Bayer Healthcare Llc Differential expression of genes in microsatellite instability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (fr) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Proteines humaines comportant des sequences de signaux secretoires et adn codant ces proteines
WO1998016640A1 (fr) * 1996-10-11 1998-04-23 Incyte Pharmaceuticals, Inc. Proteine humaine reg i-gamma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039541A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Gene et proteine specifiques du colon
US5861494A (en) * 1995-06-06 1999-01-19 Human Genome Sciences, Inc. Colon specific gene and protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (fr) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Proteines humaines comportant des sequences de signaux secretoires et adn codant ces proteines
WO1998016640A1 (fr) * 1996-10-11 1998-04-23 Incyte Pharmaceuticals, Inc. Proteine humaine reg i-gamma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM S ET AL: "Ectopic expression of reg protein: A marker of colorectal mucosa at risk for neoplasia." GASTROENTEROLOGY, vol. 110, no. 4 SUPPL., 1996, page A1398 XP008003777 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week;San Francisco, California, USA; May 19-22, 1996 ISSN: 0016-5085 *
LEVINE J L ET AL: "Reg I protein localization in colonic mucosa at risk for neoplasia." GASTROENTEROLOGY, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), page A635 XP008003762 Digestive Disease Week and the 99th Annual Meeting of the American Gastroenterological Association;New Orleans, Louisiana, USA; May 16-22, 1998 ISSN: 0016-5085 *
See also references of WO0020640A1 *

Also Published As

Publication number Publication date
EP1117833A4 (fr) 2002-08-14
CA2345000A1 (fr) 2000-04-13
JP2002526760A (ja) 2002-08-20
WO2000020640A1 (fr) 2000-04-13

Similar Documents

Publication Publication Date Title
US7858325B2 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US8029787B2 (en) Method of diagnosing, monitoring, staging, imaging and treating various cancers
US6902892B1 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000008210A1 (fr) Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter
US20050266483A1 (en) Novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1131095A1 (fr) Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate
EP1104486A1 (fr) Nouveau procede de diagnostic, de surveillance, de classification par stades, d'imagerie et de traitement du cancer des poumons
EP1117833A1 (fr) Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux
US6962779B1 (en) Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
WO2000023108A1 (fr) Methode de diagnostic, de suivi, de classification par stade, de visualisation et de traitement de cancer de la prostate
US6858386B1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7014996B1 (en) Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
US6869592B1 (en) Method and antibody for imaging lung cancer
CA2345285A1 (fr) Nouveau procede pour diagnostiquer, controler, etablir le bilan d'extension, visualiser, et traiter des cancers gynecologiques
CA2346326A1 (fr) Nouveau procede de diagnostic, de controle, de stadification, d'imagerie et de traitement de cancers gynecologiques ou de cancers de la prostate
US20050106620A1 (en) Novel method of diagnosing, monitoring, staging, imaging and treating cancer
WO2000012761A1 (fr) Nouvel anticorps permettant de diagnostiquer le cancer de la vessie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20020701

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

17Q First examination report despatched

Effective date: 20021021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040331